Spondyloarthropathies: progress and challenges

Best Practice and Research: Clinical Rheumatology

Volumn 22, Issue 2, 2008, Pages 325-337

  Jacques, Peggy ^a   Mielants, Herman ^a   De Vos, Martine ^a   Elewaut, Dirk ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

enthesitis; new bone formation; spondyloarthropathies; TNF

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFICACY; ENTERITIS; ENTHESITIS; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; INFLAMMATION; NONHUMAN; OSSIFICATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SPONDYLOARTHROPATHY; SYMPTOM; SYNOVITIS;

ENTERITIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIGAMENTS, ARTICULAR; OSTEOGENESIS; SPONDYLARTHROPATHIES; SYNOVIAL MEMBRANE; TENDINOPATHY; TENDONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42949086459     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2008.01.011     Document Type: Review

References (96)

1. Gran J.T., Husby G., and Hordvik M. Prevelance of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Annals of the Rheumatic Diseases 44 (1985) 359-367
2. Saraux A., Guillemin F., Guggenbuhl P., et al. Prevalence of spondyloarthropathies in France: 2001. Annals of the Rheumatic Diseases 64 10 (2005) 1431-1435
3. Braun J., Bollow M., Remlinger G., et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis & Rheumatism 41 1 (1998) 58-67
4. Davis Jr. J.C., Van Der Heijde D., Braun J., et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis & Rheumatism 48 11 (2003) 3230-3236
5. Kruithof E., Van den Bosch F., Baeten D., et al. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Annals of the Rheumatic Diseases 61 3 (2002) 207-212
6. Van Den Bosch F., Kruithof E., Baeten D., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis & Rheumatism 46 3 (2002) 755-765
7. D'Haens G., Swijsen C., Noman M., et al. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. American Journal of Gastroenterology 96 9 (2001) 2564-2568
8. Sandborn W.J., Hanauer S.B., Katz S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 5 (2001) 1088-1094
9. Baeten D., and De Keyser F. The histopathology of spondyloarthropathy. Current Molecular Medicine 4 1 (2004) 1-12
10. Baeten D., Demetter P., Cuvelier C., et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Annals of the Rheumatic Diseases 59 12 (2000) 945-953
11. Ceponis A., Konttinen Y.T., MacKevicius Z., et al. Aberrant vascularity and von Willebrand factor distribution in inflamed synovial membrane. The Journal of Rheumatology 23 11 (1996) 1880-1886
12. Reece R.J., Canete J.D., Parsons W.J., et al. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis & Rheumatism 42 7 (1999) 1481-1484
13. Veale D., Yanni G., Rogers S., et al. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis & Rheumatism 36 7 (1993) 893-900
14. Elewaut D., De Keyser F., Van Den Bosch F., et al. Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. The Journal of Rheumatology 25 10 (1998) 1932-1937
15. Baeten D., Van Damme N., Van den Bosch F., et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Annals of the Rheumatic Diseases 60 8 (2001) 750-755
16. Canete J.D., Martinez S.E., Farres J., et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Annals of the Rheumatic Diseases 59 4 (2000) 263-268
17. Kraan M.C., Haringman J.J., Post W.J., et al. Immunohistological analysis of synovial tissue for differential diagnosis in early arthritis. Rheumatology (Oxford) 38 11 (1999) 1074-1080
18. Smeets T.J., Dolhain R.J., Breedveld F.C., et al. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. The Journal of Pathology 186 1 (1998) 75-81
19. Kruithof E., Baeten D., Van den Bosch F., et al. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Annals of the Rheumatic Diseases 64 4 (2005) 529-536
20. Baeten D., Demetter P., Cuvelier C.A., et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. The Journal of Pathology 196 3 (2002) 343-350
21. Baeten D., Kruithof E., De Rycke L., et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Research & Therapy 7 2 (2005) R359-R369
22. Rufai A., Ralphs J.R., and Benjamin M. Structure and histopathology of the insertional region of the human Achilles tendon. Journal of Orthopaedic Research 13 4 (1995) 585-593
23. Benjamin M., and McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. Journal of Anatomy 199 Pt 5 (2001) 503-526
24. Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis. Annals of the Rheumatic Diseases 30 3 (1971) 213-223
25. Benjamin M., Moriggl B., Brenner E., et al. The 'enthesis organ' concept: why enthesopathies may not present as focal insertional disorders. Arthritis & Rheumatism 50 10 (2004) 3306-3313
26. Moriggl B., Jax P., Milz S., et al. Fibrocartilage at the entheses of the suprascapular (superior transverse scapular) ligament of man-a ligament spanning two regions of a single bone. Journal of Anatomy 199 Pt 5 (2001) 539-545
27. McGonagle D., Lories R.J., Tan A.L., et al. The concept of a 'synovio-entheseal complex' and its implications for understanding of inflammation and damage in psoriatic arthritis and beyond. Arthritis & Rheumatism 56 8 (2007 Aug) 2482-2491 [Review]
28. Benjamin M., Toumi H., Suzuki D., et al. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis & Rheumatism 56 1 (2007) 224-233
29. Francois R.J., Gardner D.L., Degrave E.J., et al. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis & Rheumatism 43 9 (2000) 2011-2024
30. Muche B., Bollow M., Francois R.J., et al. Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis & Rheumatism 48 5 (2003) 1374-1384
31. De Keyser F., Elewaut D., De Vos M., et al. Bowel inflammation and the spondyloarthropathies. Rheumatic Diseases Clinics of North America 24 (1998) 785-813
32. Moller P., Vinje O., Kass E., et al. The distribution of clinical findings in Bechterew's syndrome (ankylosing spondylitis) suggests distinct genetic subgroups. Clinical Genetics 22 4 (1982) 151-159
33. Leirisalo-Repo M., Turunen U., Stenman S., et al. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis & Rheumatism 37 1 (1994) 23-31
34. Vander Cruyssen B., Peeters H., Hoffman I.E., et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients. Clinical and Experimental Immunology 140 2 (2005) 354-359
35. Mielants H., Veys E.M., De Vos M., et al. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. The Journal of Rheumatology 22 12 (1995) 2266-2272
36. Mielants H., Veys E.M., Cuvelier C., et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. The Journal of Rheumatology 22 12 (1995) 2273-2278
37. Mielants H., Veys E.M., Cuvelier C., et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. The Journal of Rheumatology 22 12 (1995) 2279-2284
38. De Vos M., Mielants H., Cuvelier C., et al. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 110 6 (1996) 1696-1703
39. Cuvelier C., Barbatis C., Mielants H., et al. Histopathology of intestinal inflammation related to reactive arthritis. Gut 28 4 (1987) 394-401
40. Peeters H., Vander Cruyssen B., Laukens D., et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Annals of the Rheumatic Diseases 63 9 (2004) 1131-1134
41. Palm O., Moum B., Ongre A., et al. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). The Journal of Rheumatology 29 3 (2002) 511-515
42. Purrmann J., Zeidler H., Bertrams J., et al. HLA antigens in ankylosing spondylitis associated with Crohn's disease. Increased frequency of the HLA phenotype B27, B44. The Journal of Rheumatology 15 11 (1988) 1658-1661
43. de Vlam K., Mielants H., Cuvelier C., et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. The Journal of Rheumatology 27 12 (2000) 2860-2865
44. Steer S., Jones H., Hibbert J., et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. The Journal of Rheumatology 30 3 (2003) 518-522
45. Reveille J.D. Major histocompatibility genes and ankylosing spondylitis. Best Practice & Research. Clinical Rheumatology 20 3 (2006) 601-609
46. Schroder M., and Kaufman R.J. ER stress and the unfolded protein response. Mutation Research 569 1-2 (2005) 29-63
47. Taurog J.D., Richardson J.A., Croft J.T., et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. The Journal of Experimental Medicine 180 6 (1994) 2359-2364
48. Taurog J.D., Maika S.D., Simmons W.A., et al. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. Journal of Immunology (Baltimore, Md.: 1950) 150 9 (1993) 4168-4178
49. Hammer R.E., Maika S.D., Richardson J.A., et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 63 5 (1990) 1099-1112
50. Tran T.M., Dorris M.L., Satumtira N., et al. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis & Rheumatism 54 4 (2006) 1317-1327
51. Enlow R.W., Bias W.B., and Arnett F.C. The spondylitis of inflammatory bowel disease. Evidence for a non-HLA linked axial arthropathy. Arthritis & Rheumatism 23 12 (1980) 1359-1365
52. Ogura Y., Bonen D.K., Inohara N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 6837 (2001) 603-606
53. Hugot J.P., Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 6837 (2001) 599-603
54. Hampe J., Cuthbert A., Croucher P.J., et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. The Lancet 357 9272 (2001) 1925-1928
55. Laukens D., Peeters H., Marichal D., et al. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Annals of the Rheumatic Diseases 64 6 (2005) 930-935
56. Miceli-Richard C., Zouali H., Lesage S., et al. CARD15/NOD2 analyses in spondylarthropathy. Arthritis & Rheumatism 46 5 (2002) 1405-1406
57. Crane A.M., Bradbury L., van Heel D.A., et al. Role of NOD2 variants in spondylarthritis. Arthritis & Rheumatism 46 6 (2002) 1629-1633
58. Laukens D., Peeters H., Cruyssen B.V., et al. Altered gut transcriptome in spondyloarthropathy. Annals of the Rheumatic Diseases 65 10 (2006) 1293-1300
59. Tuzun A., Erdil A., Inal V., et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clinical Biochemistry 35 7 (2002) 569-572
60. Aimone-Gastin I., Cable S., Keller J.M., et al. Studies on peroxisomes of colonic mucosa in Crohn's disease. Digestive Diseases and Sciences 39 10 (1994) 2177-2185
61. Duerr R.H., Taylor K.D., Brant S.R., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 5804 (2006) 1461-1463
62. Peyrin-Biroulet L., Parmentier-Decrucq E., Branche J., et al. IL-23R, a novel susceptibility gene for inflammatory bowel disease. Médecine Sciences 23 3 (2007) 250-252
63. Yen D., Cheung J., Scheerens H., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. The Journal of Clinical Investigation 116 5 (2006) 1310-1316
64. Rahman P., Inman R.D., Gladman D.D., et al. Association of IL-23R variants and ankylosing spondylitis. Annals of the Rheumatic Diseases 66 Suppl. II (2007) 83
65. Reveille J.D., Zhou X., Bradbury L.A., et al. IL-23R is a major determinant of ankylosing spondylitis risk - the TASC study. Annals of the Rheumatic Diseases 66 Suppl. II (2007) 112
66. Capon F., Di Meglio P., Szaub J., et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Human Genetics 122 2 (2007 Sep) 201-206
67. Elliott M.J., Maini R.N., Feldmann M., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. The Lancet 344 8930 (1994) 1105-1110
68. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. The Lancet 354 9194 (1999) 1932-1939
69. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. The New England Journal of Medicine 343 22 (2000) 1594-1602
70. Smolen J.S., Van Der Heijde D.M., St Clair E.W., et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis & Rheumatism 54 3 (2006) 702-710
71. St Clair E.W., van der Heijde D.M., Smolen J.S., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis & Rheumatism 50 11 (2004) 3432-3443
72. Manadan A.M., James N., and Block J.A. New therapeutic approaches for spondyloarthritis. Current Opinion in Rheumatology 19 3 (2007) 259-264
73. Baraliakos X., Listing J., Rudwaleit M., et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Annals of the Rheumatic Diseases 64 10 (2005) 1462-1466
74. Braun J., Landewe R., Hermann K.G., et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis & Rheumatism 54 5 (2006) 1646-1652
75. Braun J., Landewe R., Hermann K.G., et al. Sustained reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab. Annals of the Rheumatic Diseases 66 Suppl. II (2007) 85
76. Van der Heijde D., Landewe R., Deodar A., et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment not inhibited with infliximab. Annals of the Rheumatic Diseases 66 Suppl. II (2007) 85
77. Van der Heijde D., Landewe R., and Tsuji W. Two-year etanercept therapy does not inhibit radiographic progression in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 65 Suppl. II (2006) 81
78. Wanders A., Heijde D., Landewe R., et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis & Rheumatism 52 6 (2005) 1756-1765
79. Lories R.J., Derese I., de Bari C., et al. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis & Rheumatism 56 2 (2007) 489-497
80. Bafico A., Liu G., Yaniv A., et al. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nature Cell Biology 3 7 (2001) 683-686
81. Glinka A., Wu W., Delius H., et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 391 6665 (1998) 357-362
82. Diarra D., Stolina M., Polzer K., et al. Dickkopf-1 is a master regulator of joint remodeling. Natural Medicines 13 2 (2007) 156-163
83. Schett G., Landewe R., and van der Heijde D. Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?. Annals of the Rheumatic Diseases 66 6 (2007) 709-711
84. Guignard S., Gossec L., Salliot C., et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Annals of the Rheumatic Diseases 65 12 (2006) 1631-1634
85. Doubremelle M., Bourreille A., Zerbib F., et al. Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study. Gastroenterologie Clinique Et Biologique 26 11 (2002) 973-979
86. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. The Lancet 359 9317 (2002) 1541-1549
87. Sandborn W.J., Hanauer S., Loftus Jr. E.V., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. American Journal of Gastroenterology 99 10 (2004) 1984-1989
88. Youdim A., Vasiliauskas E.A., Targan S.R., et al. A pilot study of adalimumab in infliximab-allergic patients. Inflammatory Bowel Diseases 10 4 (2004) 333-338
89. Papadakis K.A., Shaye O.A., Vasiliauskas E.A., et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. American Journal of Gastroenterology 100 1 (2005) 75-79
90. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 2 (2006) 323-333
91. Braun J., Baraliakos X., Listing J., et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis & Rheumatism 57 4 (2007) 639-647
92. Haibel H., Rudwaleit M., Brandt H.C., et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis & Rheumatism 54 2 (2006) 678-681
93. van der Heijde D., Kivitz A., Schiff M.H., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism 54 7 (2006) 2136-2146
94. Van den Brande J.M., Braat H., van den Brink G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 7 (2003) 1774-1785
95. Boirivant M., Marini M., Di Felice G., et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 116 3 (1999) 557-565
96. Ina K., Itoh J., Fukushima K., et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. Journal of Immunology (Baltimore, Md.: 1950) 163 2 (1999) 1081-1090